Editas Medicine Announces U.S. Patent and Trademark Office Grants the Broad Institute Priority Benefit in CRISPR Interference...
September 11 2020 - 7:00AM
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing
company, announced today the U.S. Patent and Trademark Office
(USPTO) issued a decision in an interference between the University
of California, the University of Vienna, Emmanuelle Charpentier
(CVC) and the Broad Institute, Inc. (Broad) regarding certain Broad
CRISPR/Cas9 patents Editas Medicine exclusively licenses. The USPTO
granted Broad’s motion for priority benefit while denying CVC
priority benefit to its two earliest provisional patent
applications. As a result, Broad will enter the priority phase of
the interference as “Senior Party” while CVC remains the “Junior
Party” for purposes of determining which entity was the first to
invent the inventions at issue.
“We are pleased with the U.S. Patent and Trademark Office’s
decision, granting Broad’s motion for priority benefit. We look
forward to the proceedings, and we remain confident in our
foundational patent portfolio that we in-license from the Broad
Institute. While these proceedings are ongoing and will take time,
we believe the outcome will ultimately be positive for the Broad
Institute and their innovative and fundamental work on CRISPR/Cas9
gene editing,” said Cynthia Collins, President and Chief Executive
Officer, Editas Medicine.
The Broad patents continue to be valid and in force.
Foundational claims covering the use of CRISPR/Cas9 for gene
editing in eukaryotic cells have also issued to Broad as patents in
each of the United States, Australia, Europe, Japan, China and
other jurisdictions.
About Editas MedicineAs a
leading genome editing company, Editas Medicine is focused on
translating the power and potential of the CRISPR/Cas9 and
CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a
robust pipeline of treatments for people living with serious
diseases around the world. Editas Medicine aims to discover,
develop, manufacture, and commercialize transformative, durable,
precision genomic medicines for a broad class of diseases. For the
latest information and scientific presentations, please visit
www.editasmedicine.com.
Forward-Looking Statements This press release
contains forward-looking statements and information within the
meaning of The Private Securities Litigation Reform Act of 1995.
The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’
‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’
‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’
‘‘would,’’ and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. The Company may not
actually achieve the plans, intentions, or expectations disclosed
in these forward-looking statements, and you should not place undue
reliance on these forward-looking statements. Actual results
or events could differ materially from the plans, intentions and
expectations disclosed in these forward-looking statements as a
result of various factors, including: uncertainties inherent with
litigation, including patent interference proceedings;
uncertainties inherent in the initiation and completion of
pre-clinical studies and clinical trials and clinical development
of the Company’s product candidates; availability and timing of
results from pre-clinical studies and clinical trials; whether
interim results from a clinical trial will be predictive of the
final results of the trial or the results of future trials;
expectations for regulatory approvals to conduct trials or to
market products and availability of funding sufficient for the
Company’s foreseeable and unforeseeable operating expenses and
capital expenditure requirements. These and other risks are
described in greater detail under the caption “Risk Factors”
included in the Company’s most recent Quarterly Report on Form
10-Q, which is on file with the Securities and Exchange Commission,
and in other filings that the Company may make with the Securities
and Exchange Commission in the future. Any forward-looking
statements contained in this press release represent the
Company’s views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent date.
Except as required by law, the Company explicitly disclaims
any obligation to update any forward-looking statements.
Contacts:
Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Investors
Mark Mullikin
(617) 401-9083
mark.mullikin@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Apr 2023 to Apr 2024